Summit Therapeutics Publishes Scientific Updates to Corporate Website
May 06 2021 - 7:00AM
Cambridge, MA, May 5, 2021 - Summit
Therapeutics Inc. (NASDAQ: SMMT) today announced that we have
updated the scientific and related content on our corporate website
with respect to our investigational drug, ridinilazole, which is
currently enrolling patients in its Phase 3 clinical
trials.
The content provides scientific data in a consumable manner,
summarizing the work performed to date with respect to
ridinilazole, our precision antibiotic targeting C.
difficile. It provides details surrounding the relationship
between the human gut microbiome and recurrence of C. diff.
infection. It also describes how ridinilazole has, thus far,
shown a significant relative sparing of the microbiome compared to
the broad-spectrum antibiotics that are the current standard of
care for C. diff. treatment today.
We believe you will enjoy reading the content, and we look
forward to your feedback as we continue on our important journey
seeking regulatory approval for ridinilazole, with the goal of its
use as first-line therapy to treat initial infection and reduce
recurrence of C. diff. infection.
The specific content can be found at
https://www.summittxinc.com/our-programmes/c-difficile-infection.
About C. difficile
InfectionClostridioides difficile, or C. difficile,
infection (CDI) is a bacterial infection of the colon that produces
toxins causing inflammation of the colon and severe watery
diarrhea, painful abdominal cramping, nausea, fever, and
dehydration. CDI can also result in more serious disease
complications, including bowel perforation, sepsis, and
death. CDI is a contagious infectious disease that represents
a serious healthcare issue in hospitals, long-term care homes, and
the wider community. Summit estimates that there are
approximately 500,000 cases of CDI each year across the United
States based on a meta-analysis published in the Journal of Global
Health, June 2019.
About Summit TherapeuticsSummit
Therapeutics, empowered by its Discuva Platform, the Company’s
innovative antibiotic discovery engine, supported by BARDA and
CARB-X funding, intends to be the leader in patient-friendly and
paradigm-shifting innovation while being an ally to
physicians. Our new mechanism antibiotics are designed to
become the patient-friendly, new-era standard of care, by working
in harmony with the human microbiome to treat prospective patients
suffering from infectious disease, initially focusing on
Clostridioides difficile infections (CDI). The overriding
objective of Summit Therapeutics is to create value for patients,
hospital infectious disease caregivers, and community-based
infectious disease healthcare providers, as well as healthcare
payers around the world. We seek to create value by
developing drugs with high therapeutic efficacy - curing the cause
of the patient's condition with minimal or zero disease recurrence
or antimicrobial resistance, for the longest extent possible - and
minimizing the trauma caused to the patient and healthcare
ecosystem by minimizing serious side effects, disease recurrence,
and inaccessibility to our treatments as a result of financial or
other barriers. Currently, Summit’s lead product candidate,
ridinilazole, is engaged in two pivotal global Phase 3 trials,
Ri-CoDIFy 1 & 2, each enrolling approximately 680 patients vs.
the standard of care (vancomycin) for the treatment and reduction
of recurrence of C. difficile infections in addition to an
adolescent trial, Ri-CoDIFy 3. Commercialization of
ridinilazole for the treatment and the reduction of recurrence of
CDI is subject to regulatory approvals.
For more information, please visit
www.summittxinc.com and follow us on Twitter @summitplc. For more
information on the Company’s Discuva Platform, please visit
https://www.summittxinc.com/our-science/discuva-platform.
Contact Summit Investor
Relations:Dave GancarzVice President, Investor Relations
& Corporate Strategydavid.gancarz@summitplc.com
General Inquiries:
investors@summitplc.com
Summit Forward-looking
StatementsAny statements in this press release about the
Company’s future expectations, plans and prospects, including but
not limited to, statements about the clinical and preclinical
development of the Company’s product candidates, the therapeutic
potential of the Company’s product candidates, the potential
commercialization of the Company’s product candidates, the timing
of initiation, completion and availability of data from clinical
trials, the potential submission of applications for marketing
approvals, the impact of the COVID-19 pandemic on the Company’s
operations and clinical trials and other statements containing the
words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict,"
"project," "should," "target," "would," and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the
uncertainties inherent in the initiation of future clinical trials,
availability and timing of data from ongoing and future clinical
trials and the results of such trials, global public health crises,
including the coronavirus COVID-19 outbreak, that may affect timing
and status of our clinical trials and operations, whether
preliminary results from a clinical trial will be predictive of the
final results of that trial or whether results of early clinical
trials or preclinical studies will be indicative of the results of
later clinical trials, expectations for regulatory approvals, laws
and regulations affecting government contracts and funding awards,
availability of funding sufficient for the Company’s foreseeable
and unforeseeable operating expenses and capital expenditure
requirements and other factors discussed in the "Risk Factors"
section of filings that the Company makes with the Securities and
Exchange Commission. Accordingly, readers should not place undue
reliance on forward-looking statements or information. In addition,
any forward-looking statements included in this press release
represent the Company’s views only as of the date of this release
and should not be relied upon as representing the Company’s views
as of any subsequent date. The Company specifically disclaims any
obligation to update any forward-looking statements included in
this press release.
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024